Low Dose Naltrexone - Health Rising

Explorations #2: The RTHM and Patient-Led Research Collaborative Long COVID Treatment Guide

by Cort Johnson | Apr 6, 2026 | Abilify, Antivirals, Baricitinib, Bezisterim, CCR5 Antagonists, Drugs, GLP-1, Guanfacine, Homepage, Ivabradine, IVIG, JAK_STAT Inhibitors, Low Dose Naltrexone, Mestinon, Rapamycin, Stellate Ganglion Block, Stimulants, Trazodone, Treatment

Check out the The free RTHM and Patient-Led Research Collaborative Long COVID Treatment Guide and why we may FDA approved drugs for long COVID quicker than you might think.

“Invisible No More”: Exploring Dr. Ruhoy’s New Treatment Guide for ME/CFS, Long COVID, etc.

by Cort Johnson | Mar 23, 2026 | Alternative Health, Connective Tissues, CoQ10, Cryotherapy, Doctors, Exercise, Herbs and Botanicals, Homepage, L-carntine/Acetylcarnitine, long COVID, Low Dose Naltrexone, Mast cell activation syndrome, ME/CFS, Mind/body, Neuroplasticity, Physical Therapy, Plasmapheresis, Psychedelics, Red Light Therapy, Ruhoy, Sleep, Spine, Treatment, Urolithin A

An in-depth exploration of Dr. Ruhoy's treatment guide "Invisible No More" for ME/CFS, long COVID and similar diseases

ME/CFS Autopsy Study Finds a Wrecked HPA Axis: The 2025 IACFS/ME Conference Report #3

by Cort Johnson | Dec 4, 2025 | Baricitinib, Bezisterim, Brain, Cortene, Drugs, GLP-1, GLP-1 agonist, Homepage, HPA axis, Locus coeruleus, Low Dose Naltrexone, Neuroinflammation, Neuroinflammation, Neuroplasticity, Norepinephrine, Research, Suramin, Treatment

A Dutch ME/CFS autopsy report findings multiple severe problems in the HPA axis of ME/CFS patients.

PrecisionLife’s Bold Attempt to Break the Code on and Beat ME/CFS and Long COVID

by Cort Johnson | Oct 27, 2025 | Artificial Intelligence, COVID-19, Energy Production, Genetics, GWAS (Genome-Wide Association Study), Homepage, Low Dose Naltrexone, Metabolism, Monocytes, Oxidative Stress, Pathogens, Research, T-cells

Geoff’s Narration The GIST This is the next in a series of blogs exploring ongoing projects in ME/CFS, FM and long COVID. The first featured the RECOVER project’s next set of long COVID clinical trials. RECOVER’s 2nd Round of Long COVID...

RECOVER’s 2nd Round of Long COVID Clinical Trials Shows Progress… and Limitations

by Cort Johnson | Oct 10, 2025 | Baricitinib, GLP-1, GLP-1 agonist, Homepage, Low Dose Naltrexone, NIH, Stellate Ganglion Block, Treatment

The RECOVER Initiative announces four more clinical trials for long COVID including low dose naltrexone, bariticinib, GLP-1 agonists, and stellate ganglion blockade.

TREATME: the Open Medicine Foundation’s Mammoth ME/CFS and Long COVID Treatment Survey Results

by Cort Johnson | Jul 11, 2025 | Abilify, Amytriptyline, Antivirals, Ativan, Baclofen, Blood Volume, Drugs, Heparin, Homepage, Ivabradine, IVIG, Ketamine, Low Dose Naltrexone, Lyrica, Mestinon, Metformin, Propanolol, Stimulants, Trazodone, Treatment

The massive TreatME survey assessed the effectiveness of 150 treatments in ME/CFS and long COVID.

Visible At Last? Are Long COVID and ME/CFS Tissue Diseases? The PolyBio 2026 Symposium Pt I

Explorations #2: The RTHM and Patient-Led Research Collaborative Long COVID Treatment Guide

“Invisible No More”: Exploring Dr. Ruhoy’s New Treatment Guide for ME/CFS, Long COVID, etc.

ME/CFS Autopsy Study Finds a Wrecked HPA Axis: The 2025 IACFS/ME Conference Report #3

PrecisionLife’s Bold Attempt to Break the Code on and Beat ME/CFS and Long COVID

RECOVER’s 2nd Round of Long COVID Clinical Trials Shows Progress… and Limitations

TREATME: the Open Medicine Foundation’s Mammoth ME/CFS and Long COVID Treatment Survey Results

Health Rising’s Quickie Summer 2026 Donation Drive

Subscribe

Lives Interrupted

Lives Interrupted Latest Story

Lives Interrupted Stats

StudyME

Simmaron Research

ME/CFS & Fibromyalgia Treatment Room

May 12th - International ME/CFS & FM Awareness Day

Stay Up to Date with ME/CFS, Long COVID and Fibromyalgia News

Thank you for signing up!

Pin It on Pinterest